CORE^® is a retrospective, multicenter registry which collects data and documents clinical outcomes in patients receiving CUBICIN. CORE^® is not a controlled clinical trial and should not be used to predict success rates in clinical practice.

CORE^® is important because it provides a real-world look at how CUBICIN is being used in a wide range of patient types within a clinical setting.

The documents below describe clinical outcomes with CUBICIN in patients with complicated skin infections, as well as bloodstream infections.

Use of CUBICIN in patients with surgical-site infections, as reported in CORE^® 2006*

CORE^® is a retrospective, multicenter registry that collects data about patients who have received CUBICIN
Of 177 patients with surgical-site infections from 45 US institutions, 148 (84%) were evaluable with reported outcomes
Includes patients with surgical-site infections alone (n=134) or with concomitant bacteremia (n=13) or a complicated skin and skin structure infection (n=1)

Representative photographs; not from actual CORE^® patients.

* Registry data may not reflect data obtained from randomized, prospective, double-blinded clinical trials.

CORE^® 2006 patients with surgical-site infections: risk factors and infection types

Risk factors ^† Creatinine clearance (CLCR) <30 mL/min.


Primary infection types CORE^® 2006 documented pathogens, treatment setting, and antibiotic use in patients with surgical-site infections


MSSA = methicillin-susceptible S. aureus
MRSA = methicillin-resistant S. aureus
^‡ Includes 3 S. aureus isolates with unreported susceptibility

Clinical outcomes with CUBICIN in CORE^® 2006 registry patients with surgical-site infections

Overall clinical success = 96% (142 of 148)

Outcomes, by primary pathogen for primary infection

^§ Clinical success is defined as clinical cure or clinical improvement. Outcomes, by treatment setting
^§ Clinical success is defined as clinical cure or clinical improvement.

Outcomes, by primary infection type
^§ Clinical success is defined as clinical cure or clinical improvement.

Outcomes, by comorbid illness ^§ Clinical success is defined as clinical cure or clinical improvement.
^|| CL, <30 mL/min.

Clinical outcomes with CUBICIN in CORE^® 2006 registry patients with surgical-site infections


Outcomes, by age ^§ Clinical success is defined as clinical cure or clinical improvement.

Outcomes, by prior antibiotic use ^§ Clinical success is defined as clinical cure or clinical improvement.

Download the 2006 Post-Marketing CORE^® Registry for Surgical Site Infections
Download the 2005 Post-Marketing CORE^® Registry for S. aureus Bacteremia
Download the 2005 Post-Marketing CORE^® Registry for Complicated Skin Infections
Download the 2004 Post-Marketing CORE^® Registry for Complicated Skin Infections
Download CUBICIN Prescribing Information
Adobe® Reader® required. Download it for free.

Indications and Important Safety Information